期刊
CANCER SCIENCE
卷 113, 期 2, 页码 587-596出版社
WILEY
DOI: 10.1111/cas.15205
关键词
CHK1 inhibitor; ERK; FGFR2; MEK inhibitor; neuroblastoma
类别
资金
- JSPS KAKENHI [JP18K07246]
This study identified a potential mechanism of resistance to CHK1 inhibitors in neuroblastoma cells, involving altered expression of FGFR2 and reactivation of the MEK/ERK signaling pathway. Targeting both CHK1 and MEK1/2 could be a promising treatment strategy for MYCN-amplified neuroblastomas.
Checkpoint kinase 1 (CHK1) plays a key role in genome surveillance and integrity throughout the cell cycle. Selective inhibitors of CHK1 (CHK1i) are undergoing clinical evaluation for various human malignancies, including neuroblastoma. In this study, one CHK1i-sensitive neuroblastoma cell line, CHP134, was investigated, which characteristically carries MYCN amplification and a chromosome deletion within the 10q region. Among several cancer-related genes in the chromosome 10q region, mRNA expression of fibroblast growth factor receptor 2 (FGFR2) was altered in CHP134 cells and associated with an unfavorable prognosis of patients with neuroblastoma. Induced expression of FGFR2 in CHP134 cells reactivated downstream MEK/ERK signaling and resulted in cells resistant to CHK1i-mediated cell growth inhibition. Consistently, the MEK1/2 inhibitor, trametinib, potentiated CHK1 inhibitor-mediated cell death in these cells. These results suggested that FGFR2 loss might be prone to highly effective CHK1i treatment. In conclusion, extreme cellular dependency of ERK activation may imply a possible application for the MEK1/2 inhibitor, either as a single inhibitor or in combination with CHK1i in MYCN-amplified neuroblastomas.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据